ZWIJNAARDE (Ghent), Belgium, August 20, 2019. MyCartis to spin out point-of-need diagnostics business in new company ANTELOPE Dx. New start-up raises 5,1 million EUR
An investment consortium, with RMM (Rudi Marien) and Saffelberg (Jos Sluys) as lead investors, has invested in the new spin-off Antelope Dx. Together with some high net worth individuals, they have invested 5,1 million EUR in the new diagnostic company that develops innovative technology and applications for point-of-care testing.
ZWIJNAARDE (Ghent), Belgium, July 17, 2019. Today, MyCartis and XVIVO Perfusion AB announce a collaboration to engage in the development of a fast diagnostic tool to timely assess the quality of donated organs during ex-vivo perfusion. Such test can guide the transplant surgeon and team on the quality of an organ, the optimal timing of the surgery and the chances of a positive outcome for the recipient.
In a recent whitepaper, MyCartis demonstrated the successful application of interleukin-1β as an indicator for inflammation in lung organs during perfusion. With results generated within 20 minutes, this test meets the required turnaround time for real-time organ assessment as well as organ follow-up. MyCartis and XVIVO decided to expand the testing panel to also enable the quantitation of organ damage next to the degree of inflammation. Both phenomena are negative indicators for successful transplantation. In line with the inflammation test, an assay fit-for-purpose in real-time organ assessment will be developed to measure at least one additional biomarker in the perfusion fluid.
13 december 2018, MyCartis announces the addition of a point-of-need testing technology, ANTELOPE Dx, to complement its immuno - assay technology offering.MyCartis continues to innovate in next generation immunodiagnostic technologies and as such it will engage in a novel point - of - need diagnostic solution named ANTELOPE Dx.
ANTELOPE Dx is an immuno - diagnostic platform in development, that aims to offer clinical lab performance with the ease - of - use of a pregnancy test at a consumer price tag.The technology originated from UGent, Belgium, under supervision of Professor Peter Bienstman, in the Photonics Research Group of Professor Roel Baets, with Jan - Willem Hoste as lead investigator.Jan - Willem Hoste will play a crucial role in the further development of the technology, the platform and the test menu.
MyCartis has made significant progress in the development of a fast (<30min) immunoassay to objectively assess the fitness of a donor organ during perfusion as well as predict the post-surgery acceptance and survival. This is the first time that an assay meets the required analytical performance criteria required in this emerging field and is ideally suited for repeat (interval) testing during the organ perfusion process. These assay characteristics are made possible through a combination of DMAT® features as well as unique Evalution® platform concepts. When implemented, the transplant surgeon would get timely insight on the organ fitness and gain confidence in the successful outcome of this life-saving procedure.
"Making more donor organs available for successful transplantation is essential in order to shorten waiting times and reduce mortality rates on the transplant waiting list. Because of their unique capability of running very fast immunoassays, we approached MyCartis to work on an assay for the real-time and timely assessment of donor organs undergoing ex-vivo perfusion."
Endorsement of MyCartis’ ISO 13485 Certificate
The December ’17 TUV surveillance audit endorses MyCartis’ ISO 13485 Certificate of Compliance.
4 - 8 August 2019
Anaheim, CA USA